Background Alopecia areata (AA) is a common hair loss disorder that results in patchy to complete hair loss. Many uncertainties exist around the most effective treatments for this condition. Objectives To identify uncertainties in AA management and treatment that are important to both service users (people with hair loss, carers and relatives) and healthcare professionals. Methods An AA priority setting partnership was established between patients, their carers and relatives, and healthcare professionals to identify the most important uncertainties in AA. The methodology of the James Lind Alliance was followed to ensure a balanced, inclusive and transparent process. Results In total, 2747 treatment uncertainties were submitted by 912 participants, of which 1012 uncertainties relating to AA (and variants) were analysed. Questions were combined into 'indicative uncertainties' following a structured format. A series of ranking exercises further reduced this list to a top 25 that were taken to a final prioritization workshop where the top 10 priorities were agreed. Conclusions We present the top 10 research priorities for AA to guide researchers and funding bodies to support studies important to both patients and clinicians.
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Background Alopecia areata (AA) is a common hair loss disorder that results in patchy to complete hair loss. Many uncertainties exist around the most effective treatments for this condition. Objectives To identify uncertainties in AA management and treatment that are important to both service users (people with hair loss, carers and relatives) and healthcare professionals. Methods An AA priority setting partnership was established between patients, their carers and relatives, and healthcare professionals to identify the most important uncertainties in AA. The methodology of the James Lind Alliance was followed to ensure a balanced, inclusive and transparent process. Results In total, 2747 treatment uncertainties were submitted by 912 participants, of which 1012 uncertainties relating to AA (and variants) were analysed. Questions were combined into 'indicative uncertainties' following a structured format. A series of ranking exercises further reduced this list to a top 25 that were taken to a final prioritization workshop where the top 10 priorities were agreed. Conclusions We present the top 10 research priorities for AA to guide researchers and funding bodies to support studies important to both patients and clinicians.
What's already known about this topic?
• Many uncertainties exist around the management and treatment of alopecia areata (AA).
What does this study add?
• We present the top 10 uncertainties in AA management and treatment that are important to service users (people with hair loss, their carers and relatives) and healthcare professionals.
• These prioritized research uncertainties can be used to guide researchers and funding bodies when deciding to invest in AA research studies.
Alopecia areata (AA) is an autoimmune hair loss disorder with a reported lifetime risk of 1Á7%.
1 AA typically presents as patchy areas of hair loss that may involve any scalp or body site. 2 The extent of hair loss can vary from a small, coin-sized patch to complete scalp hair loss (alopecia totalis) or scalp and body hair loss (alopecia universalis). The skin itself shows no evidence of inflammation or scarring. Hair loss in AA is frequently associated with psychological distress and may present with symptoms of anxiety, depression or reduction in quality of life. 3 National guidelines reflect the many uncertainties that exist about optimal therapy in AA 4 with the latest Cochrane systematic review published in 2008 concluding: 'there is no good trial evidence that any treatment provides long-term benefit to patients with alopecia areata'. 5 The James Lind Alliance (JLA) is a project funded by the National Institute of Health Research with support from the Medical Research Council. The aim of the JLA is to provide infrastructure and support to patients and clinicians working together to identify the most important treatment uncertainties affecting their particular interest, in order to stimulate and prioritize future research in that area. The Priority Setting Partnership (PSP) presented here was proposed by the British Hair and Nail Society (BHNS) to address treatment uncertainties highlighted by systematic reviews, treatment guidelines and clinical experience for AA (including alopecia totalis and alopecia universalis). Working with the JLA and funded by the hair loss charity Alopecia UK, this PSP presents priorities for U.K. hair research in a bid to raise the profile of AA and to open research funding streams to address these important uncertainties.
The objectives of the AA PSP were to (i) work with people with AA, their partners/parents/carers and healthcare providers to identify uncertainties about AA treatment and management; (ii) survey the research literature to identify uncertainties and research recommendations; (iii) agree by consensus a prioritized list of those uncertainties; (iv) translate these prioritized uncertainties into research questions that can be tested; (v) publicize the results of the PSP and the process of obtaining them; and (vi) take the results to research commissioning bodies to be considered for funding. All identified uncertainties from this process will be added to the U.K. Database of Uncertainties about the Effects of Treatments (UK-DUETs) (www.library.nhs.uk/duets).
Initially, the plan was to explore uncertainties relating to AA as part of a larger 'Hair Loss PSP' addressing all types of hair loss within the same process. However, analysis of the initial survey revealed that over half of the responses specifically related to AA (including alopecia totalis and alopecia universalis). Therefore, the Steering Group (SG) felt it was appropriate to separate the analysis at this point into two separate PSP processes that would run in parallel yet remain under the supervision of the same SG membership. The rationale for this change was to prevent one condition dominating the process, while maximizing identification of important uncertainties across all conditions studied. The Hair Loss PSP (excluding AA) is reported separately (Macbeth et al., manuscript in preparation).
Participants and methods
Following the principles and guidelines set by the JLA, the AA PSP adhered to a predetermined protocol to ensure transparency and inclusivity of all parties within the process. 6 The ) provided independent oversight of the PSP and chaired the SG to ensure that members adhered to the principles of the JLA and that no individuals unduly influenced the process. All potential conflicts of interest were declared prospectively. The academic psychologist was unable to continue with the process but submissions represented this area well and a psychologist was invited to take part in the final workshop to ensure balance. The five stages of the PSP process are outlined below and summarized in Figure 1 . cia UK website (www.alopeciaonline.org.uk). In addition, paper surveys were available on request and were also distributed at key events. Through engagement with the various partner organizations, local advertisement and via social media, a range of people with different hair loss conditions, their carers and relatives, and healthcare professions were targeted. Uncertainties were invited by asking the following question: 'Do you have questions about prevention, diagnosis or treatment of hair loss that need to be answered by research?' Participants were permitted to submit as many or as few questions as they wished, and these could relate to one or more hair loss conditions. The survey contained a participant information sheet to provide background to the process and survey text was designed to be easy to understand and provide all the relevant information for self-completion. Submitting the completed survey was considered as consent to participate in the PSP process and publish the (anonymized) uncertainties generated on UK-DUETs.
Stage 3: Collation
The aim of this stage was to review all the submitted questions, exclude questions outside the remit of the PSP and generate 'indicative uncertainties' (i.e. collation of similar questions into one clear, understandable question presented in a standard format). Nonquestions (i.e. statements or comments without questions within) and questions not directly relating to a hair loss disorder were excluded. Questions that could be resolved with reference to existing research evidence (so called 'unknown knowns') were identified from existing sources of information, in particular systematic reviews, evidence-based guidelines and prospective trial registries. Exclusion of questions or comments outside of the remit of the Alopecia Areata PSP were made by consensus within the SG. Uncertainties that were not adequately addressed by previous research were collated and will be entered into a hair loss section within UK DUETs (www.library.nhs.uk/duets).
Stage 4: Ranking of treatment uncertainties
The aim of this stage was to generate a shortlist of indicative uncertainties deemed by people with AA as well as healthcare professionals to be important. To reduce the large number of indicative uncertainties generated in stage 3 to a reasonable number for ranking, an 'interim list' was created using criteria agreed by the SG. These criteria were designed to identify which questions were asked most frequently, with weight given to questions asked by more than one person and questions asked by patients and healthcare professionals independently. This process generated a list of 51 questions to go forward to the second survey.
The second online ranking survey was completed by previous participants, by invitation, to further refine the interim list into a shortlist of 25 uncertainties to take to the final workshop. Five hundred participants from the initial survey had provided contact details and were invited to participate in the interim ranking. Eighty-seven participants (17%) returned responses for the second survey. Participants were invited to choose up to 10 uncertainties from the interim list that they considered to be most important but were not asked to prioritize them. The responses obtained were used to rank the uncertainties by number of votes. The priorities of the different groups of responders were listed separately and compared. through consensus, the most popular uncertainties relating to the management of AA from the 25 uncertainties generated by the interim process. Attendance at the final workshops was designed to represent a balanced distribution of interested parties and resulted in a good representation from patients (seven of 19) and healthcare professionals (five dermatologists, three trichologists, three GPs and a psychologist). Those attending the priority-setting workshop were asked to complete a declaration of interests, including disclosure of relationships with for-profit organizations. The final workshop was facilitated by three independent JLA facilitators to ensure fairness, transparency and accountability and to ensure no unfair influence by any individual. Using nominal group technique, 100% consensus was achieved through ranking and plenary sessions, eventually generating the top 10 research priorities. During breakout groups, the uncertainties were ranked and allocated a numerical position. The 'scores', as the sum of the numerical positions in each breakout group, were used to rank the questions for the whole group plenary discussion. Three breakout sessions and three whole-group plenaries were required to achieve consensus.
Results
The initial survey was completed by 912 participants generating 2747 responses, 83% from patients, carers and relatives and 13% from healthcare professionals (Fig. 2) . After removal of nonquestions and those deemed 'out of scope' (e.g. nonquestions/statements, and not directly relating to hair loss etc.), 1823 uncertainties remained of which 1015 related to AA.
Twenty of the 1012 submitted uncertainties could be answered from available evidence and so were excluded. Indicative uncertainties were generated by combining similar questions and standardized using the 'Population Intervention Comparator Outcome' process formatting. This process generated an interim list of 170 uncertainties that was further reduced by ranking questions based on the number of submissions, with priority given to those questions posed by both patients and healthcare professionals. The top 51 uncertainties were taken forward to the second ranking survey that ran from 22 September 2015 to 4 October 2015. The top 25 uncertainties were taken to the final workshop on 6 November 2015 to select the 'Top 10' research uncertainties by consensus (Table 1) .
Discussion
Here we present an overview of this PSP that has demonstrated a number of uncertainties relating to the management and treatment of AA. By adhering to the JLA ethos of inclusivity and transparency, and using a combination of online surveys and face-to-face workshops, we can feel confident that the outcomes generated here accurately reflect the consensus view of both service users (people with AA, carers and relatives) and healthcare professionals in determining future priorities for AA research.
Feedback from participants in the final workshop revealed that the opportunity to discuss the questions allowed different viewpoints to be aired, identified positions they had not previously considered and gave rise to a more balanced appraisal of the priorities. Thus, the final top 10 did not exactly reflect the ranking (performed independently) from the second survey. Discussion on position of ranking was frequently influenced by the other questions presented, with certain questions relegated in priority if they were deemed to be covered by other uncertainties more highly ranked in the process. Although deliverability of the research was considered in appraising each question, it was acknowledged that the questions broadly represented a theme for research that would require refinement before being developed into a completed research question. A workshop has been planned to further progress these research uncertainties to fully formed research questions and to develop vignettes. Interestingly, a significant proportion of the originally submitted questions did not represent an uncertainty at all, but reflected a lack of information around treatment options and service provision. Recurring themes included availability of services, treatment strategies, wig provision and the low priority given to hair loss in the National Health Service. Striking was the frequency of comments relating to experiences of patients accessing medical services, particularly seeing GPs, with many describing a perceived lack of knowledge, reluctance to refer and in some cases a lack of compassion when dealing with their distressing problem. Thus, a greater awareness and education of GPs/healthcare professionals around hair loss was suggested to highlight and address the (openly acknowledged) inadequate dermatology training currently received in the U.K. by many medical students and GP trainees in the field of hair loss.
Some problems were encountered during the process mainly around data handling and the large number of uncertainties originally submitted (2747 questions). By necessity a 'data team' was set up to process these results. However, some inconsistency occurred in taxonomy allocation to categorize questions. This might have been overcome by just one or two people handling the results, although this would have significantly prolonged the process in terms of time and costs. Another area of difficulty was around engagement of key stakeholders. In general, smaller and specialized organizations were keen to become partners in the process. However, some larger organizations were reluctant to commit to partnership but agreed to advertise the PSP to their members, while other groups refused to engage at all. These decisions appeared to relate to the inability of such large organizations to commit to these types of projects, which they are frequently approached to support. As the number of PSPs in all fields are likely to increase, with many groups anticipated to want engagement with similar stakeholders each time, it was felt by the SG that the JLA should consider setting up a higher-level agreement with the main stakeholder groups (particularly the royal colleges and specialist associations) to provide a minimum level of commitment for all future JLA-supported PSP processes.
We present an overview of the AA PSP process, including pitfalls encountered along the way. By presenting the top 10 uncertainties in AA identified as important by both patients and clinicians we hope to raise awareness of this disorder and influence research priorities in the future. These outcomes will be put forward to researchers and funding bodies with the ultimate aim of securing meaningful research funds to address these important issues.
